Weight-related medical conditions include high blood pressure, high cholesterol or Type 2 Diabetes
For liraglutide, treatment should be discontinued if at least 5% weight loss has not been achieved after 12 weeks at the maintenance dose
Some medication labels also warn about more severe risks, including pancreatitis, gallbladder disease, acute kidney injury, and hypersensitivity reactions
Extended use beyond 12 weeks should be discussed with your provider
This binding transcriptionally upregulates the expression of a series of key genes, including GCLC, GCLM (the light chain of GCLC), and xCT (system xc, responsible for cysteine uptake), thereby increasing GSH synthesis and cysteine uptake, thereby strengthening the cell's antioxidant defenses